Senti Biosciences Inc. [SNTI] is -61.76% lower this YTD. Is it still time to buy?

Senti Biosciences Inc. [NASDAQ: SNTI] price surged by 17.81 percent to reach at $0.57. The company report on October 5, 2022 that Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at SITC Annual Meeting.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Abstracts highlight Senti Bio’s continued progress in applying gene circuits to improve the cytotoxicity and persistence of allogeneic CAR-NK cells for the potential treatment of solid tumors.

A sum of 13251852 shares traded at recent session while its average daily volume was at 5.43M shares. Senti Biosciences Inc. shares reached a high of $4.33 and dropped to a low of $2.9215 until finishing in the latest session at $3.77.

The one-year SNTI stock forecast points to a potential upside of 57.3. The average equity rating for SNTI stock is currently 1.50, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Senti Biosciences Inc. [SNTI]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SNTI shares is $8.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SNTI stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Morgan Stanley have made an estimate for Senti Biosciences Inc. shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on October 07, 2022.

The Average True Range (ATR) for Senti Biosciences Inc. is set at 0.99, with the Price to Sales ratio for SNTI stock in the period of the last 12 months amounting to 55.09. The Price to Book ratio for the last quarter was 0.51, with the Price to Cash per share for the same quarter was set at 0.01.

SNTI Stock Performance Analysis:

Senti Biosciences Inc. [SNTI] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -42.18. With this latest performance, SNTI shares gained by 66.08% in over the last four-week period, additionally sinking by -61.96% over the last 6 months – not to mention a drop of -62.22% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SNTI stock in for the last two-week period is set at 56.07, with the RSI for the last a single of trading hit 54.62, and the three-weeks RSI is set at 56.04 for Senti Biosciences Inc. [SNTI]. The present Moving Average for the last 50 days of trading for this stock 2.36, while it was recorded at 3.80 for the last single week of trading, and 6.52 for the last 200 days.

Insight into Senti Biosciences Inc. Fundamentals:

Senti Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.20 and a Current Ratio set at 0.20.

Senti Biosciences Inc. [SNTI] Insider Position Details

There are presently around $53 million, or 32.70% of SNTI stock, in the hands of institutional investors. The top three institutional holders of SNTI stocks are: NEA MANAGEMENT COMPANY, LLC with ownership of 4,429,725, which is approximately New of the company’s market cap and around 4.10% of the total institutional ownership; PRICE T ROWE ASSOCIATES INC /MD/, holding 3,589,585 shares of the stock with an approximate value of $13.53 million in SNTI stocks shares; and ARK INVESTMENT MANAGEMENT LLC, currently with $8.3 million in SNTI stock with ownership of nearly -3.344% of the company’s market capitalization.

Positions in Senti Biosciences Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 15 institutional holders increased their position in Senti Biosciences Inc. [NASDAQ:SNTI] by around 10,211,301 shares. Additionally, 41 investors decreased positions by around 14,373,574 shares, while 1 investors held positions by with 10,438,941 shares. The mentioned changes placed institutional holdings at 14,145,934 shares, according to the latest SEC report filing. SNTI stock had 11 new institutional investments in for a total of 6,164,134 shares, while 35 institutional investors sold positions of 12,056,258 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here